Enanta Pharmaceuticals, Inc.

ENTA US29251M1062

🆔
Registration No.
2527352
💰
Capitalization
Small-cap

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

🔗
Website
https://www.enanta.com
Annual Performance 1
2021 2022 2023 2024 2025
78% -37% -79% -43% 0%
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
18
🙍
Insiders
8
Person Price Shares Total Published Completed
Luly Jay R.
CEO 		5.69
USD 		45,000
Bought 		256,050
USD 		12/02/2025 12/02/2025
Kieffer Tara Lynn
SR OFF 		8.06
USD 		2,283
Sold 		18,401
USD 		06/12/2024 06/12/2024
Mellett Paul J
SR OFF 		8.06
USD 		2,591
Sold 		20,883
USD 		06/12/2024 06/12/2024
Or Yat Sun
CSO 		8.06
USD 		2,591
Sold 		20,883
USD 		06/12/2024 06/12/2024
Luu Brendan
CBO 		8.06
USD 		2,283
Sold 		18,401
USD 		06/12/2024 06/12/2024
Rottinghaus Scott T.
CMO 		17.08
USD 		5,375
Sold 		91,805
USD 		11/07/2024 15/07/2024
Rottinghaus Scott T.
CMO 		15.04
USD 		2,271
Sold 		34,156
USD 		11/07/2024 12/07/2024
Rottinghaus Scott T.
CMO 		15.07
USD 		4,299
Sold 		64,786
USD 		11/07/2024 11/07/2024
Kieffer Tara Lynn
SR OFF 		12.33
USD 		7,266
Sold 		89,590
USD 		17/06/2024 17/06/2024
Vance Terry
 9.12
USD 		15,295
Sold 		139,490
USD 		13/12/2023 13/12/2023

Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include Enanta Pharmaceuticals, Inc. to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Historical Performance
1M 3M 6M 1Y 3Y 5Y All Time
-54% -62% -60% -75% -89% -86% -83%
Last 52W Low 52W High All-Time Low All-Time High β
11.35 4.26 15.16 4.26 15.16
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Luly Jay R. 2 325,674.90 162,837.45 05/12/2023 12/02/2025
Vance Terry 2 278,980.80 139,490.40 13/12/2023 13/12/2023
Rottinghaus Scott T. 4 195,889.19 48,972.30 05/12/2023 15/07/2024
Kieffer Tara Lynn 3 128,454.51 42,818.17 05/12/2023 06/12/2024
Mellett Paul J 2 44,111.02 22,055.51 05/12/2023 06/12/2024
Or Yat Sun 2 44,111.02 22,055.51 05/12/2023 06/12/2024
Luu Brendan 2 38,864.73 19,432.37 05/12/2023 06/12/2024
Gardiner Nathaniel S. 1 23,227.56 23,227.56 05/12/2023 05/12/2023

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.